← Eichor
Study identifier: NCT07678736 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Muscle Monitor: Early Skeletal Muscle Indicators of Insulin Resistance and Cardiometabolic Risk

Condition: Insulin Resistance · Insulin Resistance and Type 2 Diabetes · Cardiometabolic Risk Factors  ·  Sponsor: University Ghent

PhaseN/A
Planned participants250
Who can joinAll sexes, 20 Years to 30 Years
Healthy volunteersNo

About this study

Insulin resistance is an early etiological factor in the development of type-2 diabetes (T2D), which constitutes a large societal health burden with an expected additional rise in the years to come. Skeletal muscle is the body's largest lean tissue mass and the major site of glucose disposal in response to insulin stimulation. Prior studies have suggested that a fast skeletal muscle phenotype, including a predominant fast muscle fiber composition, reduced capillary density, low fat oxidation and muscle oxidative capacity may be implicated in insulin resistance and TD2 development. However, key questions pertain in relation to the cause and effect of these relationships as well as the interaction with potential confounders and effect-modifiers including life-style factors (e.g. diet and physical activity levels) and general participant characteristics (e.g. body composition and training status). In the present project, we therefore aim to derive muscle fiber type and extensively map the proteomic signature of the early stages of insulin resistance in a large cross-sectional study using a young and apparently healthy cohort prior to T2D development, including a thorough participant characterization. We will recruit \~250 participants (men and women) in the age of 20-30 years and conduct extensive phenotyping and tissue sampling across one laboratory-based test day and a scan visit, as well as measurements of physical activity level and glucose handling in free-living conditio…

This description comes directly from the study's public registry record.

Talk to the study team

Eline Lievens, Professor  ·  00320478312585  ·  eline.lievens@ugent.be

Jeppe Foged Vigh-Larsen, PhD  ·  004529870635  ·  jeppefoged.vighlarsen@ugent.be

Always discuss trial participation with your own doctor first.

Locations (1)

Ghent UniversityGhent, East Flanders, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07678736